Pham et al. are currently evaluating the adoption of a smartphone application in which patients can check their PSA, submit monthly PROMs relating to their prostate cancer-specific quality of life, and access a feed of educational content and survivorship-related social events. This evidence concerns the gene KLK3 and prostate carcinoma.